Phaseline

Targets › PKC

PKC: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on PKC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Deciphera PharmaceuticalsInlexisertib (DCC-3116)
Protein kinase C (PKC) inhibitor
PKCPhase 1GISTMar 2027

Conditions

GIST (1)

Modalities

small molecule (1)

Companies

Deciphera Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.